Navigation auf uzh.ch

Suche

CRPP Viral Infectious Diseases

Original articles in peer reviewed journals from the Zurich Primary HIV Infection Study prior to CRPP

A) Original articles in peer reviewed journals

  1. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Medicine. 2005:11:615-622. (IF 22.9 / cited by 277)
     
  2. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A. Virus isolates during acute and chronic Human Immunodeficiency Virus Type 1 infection show distinct patterns of sensitivity to entry inhibitors. Journal of Virology. 2005;79:8454-8469. (IF 5.1 / cited by 61)
     
  3. Joos B, Trkola A, Aceto L, Fischer M, Vcelar B, Stiegler G, Katinger H, Kuster H, Günthard HF. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrobial Agents and Chemotherapy. 2006;50:1773-1779. (IF 4.6 / cited by 41)
     
  4. Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederöst B, Weber R, von Wyl V, Günthard HF, Trkola A. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLOS Medicine. 2006;3:2078-2093. (e441). (IF 15.3 / cited by 64)
     
  5. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Weber R, Stiegler G, Katinger H, Günthard HF, Trkola A. In vivo and in vitro escape to neutralizing antibodies 2G12, 2F5 and 4E10. Journal of Virology, 2007;81:8793-8808, published online ahead of print. doi:10.1128/JVI.00598-07 (IF 5.1 / cited by 59)
     
  6. Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, Günthard HF. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: Estimates for protective titers. Journal of Virology. 2008;82:1591-1599. (IF 5.1 / cited by 33)
     
  7. Huber M, von Wyl V, Ammann CA, Kuster H, Stiegler G, Katinger H, Weber R, Fischer M, Stoiber H, Günthard HF, Trkola A. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. Journal of Virology. 2008;82:3834-3842. (IF 5.1 / cited by 15)
     
  8. Rusert P, Mann A, Huber M, von Wyl V, Günthard HF, Trkola A. Divergent effects of cell environment on HIV entry inhibitor activity. AIDS. 2009;23:1319-1327. (IF 6.4 / cited by 15)
     
  9. Mann AM, Rusert P, Berlinger L, Kuster H, Günthard HF, Trkola A. HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS. 2009; 23(13):1659-67. (IF 6.4 / cited by 25)
     
  10. Metzner K, Rauch P, Von Wyl V, Leemann C, Grube C, Kuster H, Böni J, Weber R, Günthard HF. Efficient suppression of minority quasispecies of drug-resistant viruses present at primary HIV-1 infection by RTV-boosted protease inhibitor containing antiretroviral therapy. Journal of Infectious Diseases. 2010;201:1063-1071. (IF 5.8 / cited by 35)
     
  11. Joos B, Rieder P, Fischer M, Kuster H, Rusert P, Trkola A, Pillai SK, Wong JK, Weber R, Günthard HF. Association between specific HIV-1 Env traits and virologic control in vivo. Infection Genetics and Evolution. 2010;10:365-372. (IF 2.8 / cited by 1)
     
  12. Rieder P, Joos B, von Wyl V, Kuster H, Grube C, Leemann C, Böni J, Yerly S, Klimkait T, Bürgisser P, Weber R, Fischer M, Günthard HF, and the Swiss HIV Cohort Study. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS. 2010;24:1177-1183. (IF 6.4 / cited by 35)
     
  13. Haas A, Rehr M, Graw F, Rusert P, Bossart W, Kuster H, Trkola A, Günthard HF, Oxenius A. HIV-1 replication activates CD4+ T cells with specificities for persistent Herpes viruses. EMBO Molecular Medicine. 2010;2:231-244. (IF 7.8 / cited by 10)
     
  14. Schmid A, Gianella S, von Wyl V, Metzner KJ, Scherrer AU, Niederöst B, Althaus CF, Rieder P, Grube C, Joos B, Weber R, Fischer M, Günthard HF. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One. 2010;5(10):e13310. (IF 3.7 / cited by 30)
     
  15. Kouyos RD, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Rauch A, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard HF, and the Swiss HIV Cohort Study. Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical Infectious Diseases. 2011;52(4):532-539. (IF 9.4 / cited by 38)
     
  16. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Günthard HF, Rusert P, Trkola A. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. Journal of Experimental Medicine. 2011;208(3):439-54. (IF 13.2 / cited by 41)
     
  17. Gianella S, von Wyl V, Fischer M, Niederoest B, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF, and the Swiss HIV Cohort Study. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antiviral Therapy.2011;16(4):535-545. (IF 3.1 / cited by 22)
     
  18. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, Regoes RR, Günthard HF, Trkola A. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Ex Med. 2011;208(7):1419-33. (IF 13.2 / cited by 37)
     
  19. Metzner KJ, Leemann C, Di Giallonardo F, Grube C, Scherrer AU, Braun D, Kuster H, Weber R, Günthard HF. Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection. PLoS One. 2011; 6(7):e21734. (IF 3.7 / cited by 3)
     
  20. von Wyl V, Gianella S, Fischer M, Niederoest, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF, and the Swiss HIV Cohort Study. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One. 2011;6(11):e27463. (IF 3.7 / cited by 10)
     
  21. Rieder P, Joos B, Scherrer AU, Kuster H, Braun D, Grube C, Niederöst B, Leemann C, Gianella S, Metzner KJ, Böni J, Weber R, Günthard HF. Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. Clinical Infectious Diseases. 2011;53(12):1271-1279. (IF 9.4 / cited by 23)
     
  22. Stadler T, Kouyos R, von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Joos B, Rieder P, Xie D, Günthard HF, Drummond AJ, Bonhoeffer S, and the Swiss HIV Cohort Study. Estimating the basic reproductive number from viral sequence data. Molecular Biology and Evolution. 2012; 29(1):347–357. (IF 10.5 / cited by 27)
     
  23. Abela IA*, Berlinger L*, Schanz M, Reynell L, Günthard HF, Rusert P, Trkola A. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathogens. 2012;8(4):e1002634. [* equal contribution] (IF 8.1 / cited by 42)
     
  24. Althaus CF, Vongrad V, Niederöst B, Joos B, Di Giallonardo F, Rieder P, Pavlovic J, Trkola A, Günthard HF*, Metzner KJ*, Fischer M. Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. Retrovirology. 2012;9:27:1-13. doi:10.1186/1742-4690-9-27. [* equal contribution] (IF 4.8 / cited by 21)
     
  25. Schüpbach J, Bisset LR, Gebhardt MD, Regenass S, Bürgisser P, Gorgievski M, Klimkait T, Andreutti C, Martinetti G, Niederhauser C, Yerly S, Pfister S, Schultze D, Brandenberger M, Schöni-Affolter F, Scherrer AU, Günthard HF, and the Swiss HIV Cohort Study. Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. BMC Infectious Diseases. 2012;12(1):88. (IF 3.0 / cited by 3)

B) case reports

  1. Aceto L, Karrer U, Grube C, Oberholzer R, Hasse B, Presterl E, Böni J, Kuster H, Trkola A, Weber R, Günthard HF. Die Akute HIV Infektion in Zürich: 2002 – 2004. Schweizerische Rundschau Medizin (PRAXIS). 2005;94:1199-1205. (IF not defined)
     
  2. Von Both U, Laffer R, Grube C, Bosshart W, Gaspert A, Günthard HF. Acute CMV colitis presenting during primary HIV infection: An unusual case of an Immune Reconstitution Syndrome. Clinical Infectious Diseases. 2008;46:e38-40. (IF 9.4 / cited by 7)